Header Logo

Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Zamore, Phillip
PropertyValue
overview

Phillip D. Zamore, Ph.D., the Gretchen Stone Cook Professor of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Investigator of the Howard Hughes Medical Institute, is Chair of the RNA Therapeutics Institute, which was established at the University of Massachusetts Medical School in 2009. Zamore received his A.B. and Ph.D. degrees in Biochemistry and Molecular Biology from Harvard University. He then pursued postdoctoral studies at MIT and the Whitehead Institute for Biomedical Research.

The Zamore laboratory studies small RNA silencing pathways in eukaryotes and prokaryotes, including the RNA interference (RNAi), microRNA, and PIWI-interacting RNA pathways. Zamore and his collaborators seek to use the fundamental insights gained from studies in model and non-model bacteria, insects, and mammals to design therapies for human diseases, including Huntington’s disease. 

In 2015, Zamore was awarded the Chancellor’s Medal for Excellence in Scholarship at the University of Massachusetts Medical School. To date, Zamore has more than 125 publications and has been among the most highly cited researchers for more than a decade. 

Zamore was elected a Fellow of the National Academy of Inventors in 2014 and was selected in 2015 by Nature Biotechnology as one of the Top 20 Translational Researchers of 2014. In 2002, Zamore co-founded Alnylam Pharmaceuticals, a publicly traded biotech company which now has more than 200 employees and currently has more than six drugs in clinical trials. In 2014, he co-founded Voyager Therapeutics. He serves on the scientific advisory boards of Alnylam, Voyager, and RaNA Therapeutics.

Understanding the molecular mechanisms of post-transcriptional gene regulation.
 
How do animal embryos regulate the localization, translation, and stability of mRNAs?
In Drosophila, mRNA encoding the transcription factor, hunchback, is present throughout the embryo, but is translated into protein only in the anterior half of the cell. Two proteins, NANOS and PUMILIO. are required to repress hunchback translation in the posterior half of the fly embryo. PUMILIO binds RNA through a novel RNA-binding motif found in proteins that control developmental decisions in yeast, slime mold, and worms, and is more than 80% identical to a protein of unknown function in humans. A major goal of our laboratory is to learn how PUMILIO and NANOS control hunchback mRNA translation and to determine the biological role of the human PUMILIO protein.
 
For more information, please visit our lab website and our Howard Hughes Medical Institute web page. 
 
 

 

overview

Phillip D. Zamore, Ph.D., the Gretchen Stone Cook Professor of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Investigator of the Howard Hughes Medical Institute, is Chair of the RNA Therapeutics Institute, which was established at the University of Massachusetts Medical School in 2009. Zamore received his A.B. and Ph.D. degrees in Biochemistry and Molecular Biology from Harvard University. He then pursued postdoctoral studies at MIT and the Whitehead Institute for Biomedical Research.

The Zamore laboratory studies small RNA silencing pathways in eukaryotes and prokaryotes, including the RNA interference (RNAi), microRNA, and PIWI-interacting RNA pathways. Zamore and his collaborators seek to use the fundamental insights gained from studies in model and non-model bacteria, insects, and mammals to design therapies for human diseases, including Huntington’s disease. 

In 2015, Zamore was awarded the Chancellor’s Medal for Excellence in Scholarship at the University of Massachusetts Medical School. To date, Zamore has more than 125 publications and has been among the most highly cited researchers for more than a decade. 

Zamore was elected a Fellow of the National Academy of Inventors in 2014 and was selected in 2015 by Nature Biotechnology as one of the Top 20 Translational Researchers of 2014. In 2002, Zamore co-founded Alnylam Pharmaceuticals, a publicly traded biotech company which now has more than 200 employees and currently has more than six drugs in clinical trials. In 2014, he co-founded Voyager Therapeutics. He serves on the scientific advisory boards of Alnylam, Voyager, and RaNA Therapeutics.

Understanding the molecular mechanisms of post-transcriptional gene regulation.
 
How do animal embryos regulate the localization, translation, and stability of mRNAs?
In Drosophila, mRNA encoding the transcription factor, hunchback, is present throughout the embryo, but is translated into protein only in the anterior half of the cell. Two proteins, NANOS and PUMILIO. are required to repress hunchback translation in the posterior half of the fly embryo. PUMILIO binds RNA through a novel RNA-binding motif found in proteins that control developmental decisions in yeast, slime mold, and worms, and is more than 80% identical to a protein of unknown function in humans. A major goal of our laboratory is to learn how PUMILIO and NANOS control hunchback mRNA translation and to determine the biological role of the human PUMILIO protein.
 
For more information, please visit our lab website and our Howard Hughes Medical Institute web page. 
 
 

 

One or more keywords matched the following items that are connected to Zamore, Phillip
Item TypeName
Academic Article A CCHC metal-binding domain in Nanos is essential for translational regulation.
Academic Article The Pumilio protein binds RNA through a conserved domain that defines a new class of RNA-binding proteins.
Academic Article Crystal structure of a Pumilio homology domain.
Academic Article The PUMILIO-RNA interaction: a single RNA-binding domain monomer recognizes a bipartite target sequence.
Academic Article Measuring the rates of transcriptional elongation in the female Drosophila melanogaster germ line by nuclear run-on.
Academic Article Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways.
Academic Article RISC assembly defects in the Drosophila RNAi mutant armitage.
Academic Article The protein Sex-lethal antagonizes the splicing factor U2AF to regulate alternative splicing of transformer pre-mRNA.
Academic Article RNA silencing: genomic defence with a slice of pi.
Academic Article Heterotypic piRNA Ping-Pong requires qin, a protein with both E3 ligase and Tudor domains.
Concept Genome, Insect
Concept Insect Hormones
Concept Genes, Insect
Concept Insect Proteins
Academic Article Slicing and Binding by Ago3 or Aub Trigger Piwi-Bound piRNA Production by Distinct Mechanisms.
Academic Article Rapid Screening for CRISPR-Directed Editing of the Drosophila Genome Using white Coconversion.
Academic Article The genome of the Hi5 germ cell line from Trichoplusia ni, an agricultural pest and novel model for small RNA biology.
Search Criteria
  • Insecta